Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Bristol Myers Squibb’s Opdivo receives EC approval for second-line treatment of ESCC Bristol Myers Squibb (BMS) has achieved a significant milestone with the approval of its immunotherapy drug, Opdivo (nivolumab),… bypharmanewsdailyNovember 24, 2020
